Lanzhou Military Region General Hospital
Welcome,         Profile    Billing    Logout  
 1 Trial 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ma, Shoucheng
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
NCT06521866: Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

Recruiting
2
208
RoW
Serplulimab, Chemotherapy, SABR, Targeted therapy
Fudan University
Advanced Colorectal Carcinoma, Immunotherapy
08/26
08/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ma, Shoucheng
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
NCT06521866: Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

Recruiting
2
208
RoW
Serplulimab, Chemotherapy, SABR, Targeted therapy
Fudan University
Advanced Colorectal Carcinoma, Immunotherapy
08/26
08/27

Download Options